Top Markets
Coin of the day
Elicio Therapeutics, Inc. Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc.

ELTX
Peringkat dalam Saham #24601
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to... Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
Harga Saham
$3.09
Kapitalisasi Pasar
$58.82M
Perubahan (1 hari)
0.33%
Perubahan (1 tahun)
-73.01%
Negara
US
Perdagangan Elicio Therapeutics, Inc. (ELTX)

Kategori

Jumlah saham beredar untuk Elicio Therapeutics, Inc. (ELTX)
Jumlah saham beredar per August 2026: 0
Menurut laporan keuangan terbaru dan harga saham Elicio Therapeutics, Inc., jumlah saham beredar saat ini adalah 0. Pada akhir August 2026, perusahaan memiliki 0 saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk Elicio Therapeutics, Inc. (ELTX) dari 2026 hingga 2026
Saham beredar pada akhir setiap tahun
Tahun Saham Beredar Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Saham beredar untuk perusahaan serupa atau pesaing
Perusahaan Saham Beredar Perbedaan Negara
253.90M -
US
62.19M -
NL
396.00M -
US
483.58M -
AU
- -
CH